[go: up one dir, main page]

BRPI0918508A2 - orto-aminoanilidas para o tratamento de câncer - Google Patents

orto-aminoanilidas para o tratamento de câncer

Info

Publication number
BRPI0918508A2
BRPI0918508A2 BRPI0918508A BRPI0918508A BRPI0918508A2 BR PI0918508 A2 BRPI0918508 A2 BR PI0918508A2 BR PI0918508 A BRPI0918508 A BR PI0918508A BR PI0918508 A BRPI0918508 A BR PI0918508A BR PI0918508 A2 BRPI0918508 A2 BR PI0918508A2
Authority
BR
Brazil
Prior art keywords
aminoanilides
ortho
cancer treatment
cancer
treatment
Prior art date
Application number
BRPI0918508A
Other languages
English (en)
Inventor
Chungen Liang
Guozhi Tang
Jason Christopher Wong
Xihan Wu
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0918508A2 publication Critical patent/BRPI0918508A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/64Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/77Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/80Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/341,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/42Oxygen atoms attached in position 3 or 5
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/301,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/10Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
BRPI0918508A 2008-09-17 2009-09-07 orto-aminoanilidas para o tratamento de câncer BRPI0918508A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08164509 2008-09-17
PCT/EP2009/061533 WO2010031708A2 (en) 2008-09-17 2009-09-07 Novel ortho-aminoanilides for the treatment of cancer

Publications (1)

Publication Number Publication Date
BRPI0918508A2 true BRPI0918508A2 (pt) 2015-12-08

Family

ID=41716278

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0918508A BRPI0918508A2 (pt) 2008-09-17 2009-09-07 orto-aminoanilidas para o tratamento de câncer

Country Status (13)

Country Link
US (1) US8202866B2 (pt)
EP (1) EP2334658A2 (pt)
JP (1) JP2011526936A (pt)
KR (1) KR20110043767A (pt)
CN (1) CN102149678A (pt)
AR (1) AR073513A1 (pt)
AU (1) AU2009294668A1 (pt)
BR (1) BRPI0918508A2 (pt)
CA (1) CA2734349A1 (pt)
IL (1) IL210066A0 (pt)
MX (1) MX2011002574A (pt)
TW (1) TWI378093B (pt)
WO (1) WO2010031708A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2620027T3 (es) 2008-09-03 2017-06-27 Biomarin Pharmaceutical Inc. Composiciones que incluyen derivados del ácido 6-aminohexanoico como inhibidores de HDAC
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
ES2712803T3 (es) 2011-02-28 2019-05-14 Biomarin Pharm Inc Inhibidores de histona desacetilasa
US8781041B2 (en) * 2012-07-31 2014-07-15 Hewlett-Packard Development Company, L.P. Reducing noise in a sequence of data by linear and non-linear estimation
EP2970139B1 (en) 2013-03-15 2018-05-30 BioMarin Pharmaceutical Inc. Hdac inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1643264A1 (de) * 1967-12-20 1971-06-09 Basf Ag Verfahren zur Herstellung von Aminoaniliden
IT1033046B (it) 1970-10-31 1979-07-10 Finotto Martino Procedimento di fabbricazione di benzimidazoli sostituiti
KR20100107509A (ko) * 2001-09-14 2010-10-05 9222-9129 퀘벡 인코포레이티드 히스톤 데아세틸라아제의 억제제
EP1973405A4 (en) 2006-01-12 2011-06-01 Merck Sharp & Dohme HYDROXYALKYLARYLAMID DERIVATIVES
EP1991226B1 (en) 2006-02-28 2013-03-20 Merck Sharp & Dohme Corp. Inhibitors of histone deacetylase
CN101610996A (zh) * 2006-12-19 2009-12-23 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂及其前体药物
WO2008087514A2 (en) * 2007-01-17 2008-07-24 Orchid Research Laboratories Limited Hdac inhibitors
JP2011510917A (ja) * 2008-01-29 2011-04-07 エフ.ホフマン−ラ ロシュ アーゲー 新規n−(2−アミノ−フェニル)−アミド誘導体
WO2009138338A1 (en) * 2008-05-16 2009-11-19 F. Hoffmann-La Roche Ag Novel n-(2-amino-phenyl)-acrylamides
JP2011150917A (ja) * 2010-01-22 2011-08-04 Nippon Soken Inc ガス拡散層およびそれを備える燃料電池

Also Published As

Publication number Publication date
KR20110043767A (ko) 2011-04-27
JP2011526936A (ja) 2011-10-20
TW201014834A (en) 2010-04-16
US8202866B2 (en) 2012-06-19
TWI378093B (en) 2012-12-01
WO2010031708A2 (en) 2010-03-25
EP2334658A2 (en) 2011-06-22
WO2010031708A3 (en) 2010-08-05
MX2011002574A (es) 2011-04-26
AU2009294668A1 (en) 2010-03-25
US20100069328A1 (en) 2010-03-18
IL210066A0 (en) 2011-02-28
CN102149678A (zh) 2011-08-10
AR073513A1 (es) 2010-11-10
CA2734349A1 (en) 2010-03-25

Similar Documents

Publication Publication Date Title
BR112012005594A2 (pt) tratamento de câncer
BRPI0810206A2 (pt) Método de tratar câncer
BRPI0922884A2 (pt) compostos para tratamento de câncer
BRPI0919238A2 (pt) métodos e composições para o tratamento de câncer
BRPI1013618A2 (pt) pirimidinas substituídas para o tratamento de câncer
DK2121139T3 (da) Formulations for cancer treatment
BRPI1015215A2 (pt) porções de ligação alvo armadas com amatoxina para o tratamento de câncer
BRPI0910282A2 (pt) Composto oxadiazo-antraceno para o tratamento de diabetes
BRPI0818320A2 (pt) composição para tratamento de câncer de próstata (pca)
BRPI1007972A2 (pt) composições de combinação e métodos para o tratamento de câncer
BRPI1010874A8 (pt) composição para o tratamento de câncer de próstata
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
BRPI1008566A2 (pt) métodos e composições para o diagnóstico e tratamento de câncer
BRPI0910854A2 (pt) métodos de tratamento
BRPI0813670A2 (pt) Compostos para tratamento
BRPI1009919A2 (pt) combinações de pentamidina para tratamento de câncer.
BRPI0909016A2 (pt) anticorpos úteis para o tratamento do câncer
BRPI0909164A2 (pt) método e composições para o tratamento de câncer
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
BR112012000502A2 (pt) terapia de combinação para o tratamento de diabetes
BRPI0908715A2 (pt) métodos para tratamento da psoríase
BR112012002797A2 (pt) tratamento de câncer de próstata
BR112012000098A2 (pt) Processo para identificação de compostos para tratar câncer
BRPI0812040A2 (pt) Indicações para terapia de anti-il-i-beta
EP2283862A4 (en) ANTITUMOR AGENT

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2383 DE 06-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.